Sunshine Biopharma Announces that Essential 9 is Now Available in the United States on Amazon.com

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that its recently launched micronutrients supplement, Essential 9TM, is now available in the United States on www.Amazon.com. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM is a dietary supplement tablet that contains a balanced formula of the 9 essential amino acids that the human body cannot make. In addition to Amazon.com, Essential 9 is currently available on Amazon.ca. Sunshine Biopharma anticipates that Essential 9TM will soon be available on other Amazon websites.


About Essential 9TM
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – from the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 essential amino acids in freeform and in the proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL IS NOW AVAILABLE ON AMAZON.CA

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that its recently launched
micronutrients supplement, Essential 9TM, is now available on www.Amazon.ca. On December 14, 2018, Health Canada issued NPN 80089663
through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM is a dietary supplement tablet that
contains a balanced formula of the 9 essential amino acids that the human body cannot make. Sunshine Biopharma anticipates that Essential 9TM will
soon be available on www.Amazon.com.


About Essential 9TM
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – from the
musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and
must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and
reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 Essential Amino Acids in freeform and in the
proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s
development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this
release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a ANTICANCER DRUG UNTIL 2033

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFMD”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer today announced that it has received a “Notice of Allowance” from the United States Patent and Trademark Office for a new patent application covering Adva-27a, the Company’s lead anticancer compound. The new patent (US Patent Application Number 20150353573) contains new subject matter and extends the proprietary protection of Adva-27a until 2033. Sunshine Biopharma is the sole owner of all existing intellectual property rights and patents pertaining to Adva-27a, including US Patent Number 8,236,935 issued in 2012.
“We are very excited about this significant development for Adva-27a,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “Allowance of the second Adva-27a patent application gives us 14 years of additional protection and is a validation of the unique and innovative aspects of our anticancer molecule,” he added.

Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are currently being planned to be conducted at the McGill University Hospital Centers in Montreal, Canada.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

Sunshine Biopharma Receives Health Canada Approval for Essential 9, The Company’s First Over The Counter Essential Micronutrient

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that it has received Health Canada approval for Essential 9TM, the first in a line of essential micronutrients products that the Company is planning to launch. On Friday December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM are dietary supplement tablets that contain a balanced formula of the 9 essential amino acids that the human body cannot make. Sunshine Biopharma anticipates to start shipping Essential 9TM in the second week of January 2019.

About Essential 9TM
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF Adva-27a ANTICANCER DRUG

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has signed an agreement with Crocus Laboratories Inc. (Crocus), a Montreal based company for assistance in the manufacturing of Adva-27a. Crocus will help Sunshine in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a, Sunshine’s lead anticancer compound targeted for Pancreatic Cancer. The material which will ultimately be generated by a contract manufacturing organization will be used for animal toxicity studies and clinical trials.

About Crocus Laboratories Inc.
Crocus Laboratories Inc. is a Canadian medicinal chemistry company engaged in the design and synthesis of new chemical entities, including enzyme inhibitors, receptor modulators and compound libraries. The Crocus team has extensive experience in drug discovery and development, particularly in the areas of oncology and infectious diseases. More information about Crocus is available at www.crocuslaboratories.com.

About Sunshine Biopharma’s Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com